Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,822 across all filing types
Latest filing 2021-05-03 Director's Dealing
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Director's Dealing Classification · 100% confidence The document is a company announcement regarding transactions in shares by managerial employees and their closely associated persons, which is a standard disclosure requirement under Market Abuse Regulations. This falls directly under the 'Director's Dealing' category (DIRS). Although the document mentions an attachment, the text itself serves as the official notification of these transactions, not merely an announcement of a report's publication.
2021-05-03 English
Director's Dealing 2021
Director's Dealing Classification · 99% confidence The document is titled "Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons" and explicitly references compliance with Article 19 of Regulation No. 596/2014 on Market Abuse. It details specific transactions (Acquisition due to vesting of restricted stock units) made by a Member of the Board of Directors. This type of mandatory disclosure regarding personal share transactions by company directors and executives is specifically defined as Director's Dealing (DIRS).
2021-05-03 English
6-K
Foreign Filer Report
2021-05-03 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a formal company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the total number of shares acquired, and the impact on treasury shares. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-05-03 English
Transactions in connection with share buy-back program
Transaction in Own Shares Classification · 100% confidence The document is a company announcement detailing specific transactions executed under a share buy-back program. It provides a table of daily share repurchases, the total value of shares bought, and the updated treasury share position. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS), which covers reports of a company buying back its own shares.
2021-05-03 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document text consists almost entirely of tables showing trade data (Volume, Price, Venue, Time CET) from the XCSE (Nasdaq Stockholm exchange). The codes listed in the tables (e.g., 1, 2, 3, 4, 7, 8, 10, 19, 20, 21, 22, 23, 24, 25, 26, 30, 31, 34, 37, 42, 54, 80, etc.) appear to be internal transaction codes or identifiers rather than standard SEC/regulatory filing codes (like 10-K or DEF 14A). This structure strongly suggests a record of market activity, likely related to trading or transaction reporting. Given the options, this data does not fit well into standard corporate disclosure categories like Annual Reports (10-K), Earnings Releases (ER), or Management Discussion (MDA). It is raw transactional data presented in a tabular format, which is closest in nature to supplementary data, although the format is not explicitly an XLSX file. However, since the content is purely market/trade data dumps without narrative context, and it doesn't match any specific regulatory filing type, the most appropriate fallback category for non-standard, data-heavy regulatory/market disclosures that don't fit elsewhere is 'Regulatory Filings' (RNS), or potentially 'Financial Supplement Data' (XLSX) if we interpret the tabular data as a supplement, even though the format isn't Excel. Since the data appears to be a dump of trade reports or market surveillance data (indicated by the high volume of transaction codes and timestamps), and it is not a narrative report, 'RNS' (General regulatory announcements/fallback) is the safest classification, as it represents market activity reporting that isn't a standard financial statement or management discussion. If this were a specific regulatory filing about insider trading, it would be DIRS, but these codes are too varied and numerous for simple director dealings. Therefore, RNS is the best fit as a catch-all for this type of raw market data reporting.
2021-05-03 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.